StonvexLoading…
StonvexStonvexStonvexQuiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $7.65 | $7.71 | +0.78% | 1.0M |
| 05-11 | $7.70 | $7.69 | -0.13% | 0.9M |
| 05-12 | $7.59 | $7.65 | +0.79% | 0.8M |
| 05-13 | $7.63 | $7.60 | -0.39% | 0.8M |
| 05-14 | $7.61 | $7.37 | -3.15% | 0.7M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for SGMT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for SGMT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q3 2023 2023-07-31 |
|---|---|---|---|
Revenue | $2.00M | $2.00M | $2.00M |
Operating Income | $-30.74M | $-21.27M | Not available |
Net Income | $-27.88M | $-19.73M | Not available |
EPS (Diluted) | $-2.66 | $-3.22 | Not available |
Total Assets | $96.72M | $102.92M | Not available |
Total Liabilities | $5.65M | $5.05M | Not available |
Cash & Equivalents | $75.14M | $101.84M | Not available |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available |
Shares Outstanding | 0 | 0 | Not available |